To view the PDF file, sign up for a MySharenet subscription.

ASPEN PHARMACARE HOLDINGS LIMITED - Voluntary announcement regarding the completion of a transaction with GSK

Release Date: 01/03/2017 09:00
Code(s): APN     PDF:  
Wrap Text
Voluntary announcement regarding the completion of a transaction with GSK

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Group”)


VOLUNTARY ANNOUNCEMENT REGARDING THE COMPLETION OF A TRANSACTION WITH GSK IN RESPECT
OF THE ACQUISITION OF A PORTFOLIO OF ANAESTHETICS

Shareholders are referred to the announcement released by Aspen Holdings on 12 September 2016 wherein
it was confirmed, inter alia, that Aspen Global Incorporated (“AGI”) had signed an agreement with GSK in
terms whereof AGI would acquire a portfolio of anaesthetics globally (with the exception of certain
territories, primarily North America) (“the Anaesthetics Transaction”). In consideration for the Anaesthetics
Transaction AGI would pay an initial amount of £180 million and further milestone payments of up to £100
million, based on the results of the acquired portfolio in the 36 months following completion.

Aspen Holdings is pleased to announce that this transaction completed on 28 February 2017.

Durban
1 March 2017

Sponsor:
Investec Bank Limited




About Aspen

Aspen is a leading global player in specialty, branded and generic pharmaceuticals with an extensive basket
of products that provide treatment for a broad spectrum of acute and chronic conditions experienced
through all stages of life. Aspen continues to increase the number of lives benefitting from its products,
reaching more than 150 countries.

Aspen has a strong presence in both emerging and developed countries. Its emerging market footprint
includes Sub-Saharan Africa, Latin America, South East Asia, China, Eastern Europe and the Commonwealth
of Independent States, comprising Russia and the former Soviet Republics. From a developed world
perspective Aspen is one of the leading pharmaceutical companies in Australia and has a growing presence
in other developed countries, most notably in Western Europe.
Aspen operates with an established business presence in approximately 50 countries spanning 6 continents
and employs more than 10,000 people. The Group operates 26 manufacturing facilities across 18 sites.
Aspen holds international manufacturing approvals from some of the most stringent global regulatory
agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities are scalable to demand and
cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs
and infant nutritionals.

Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical company
listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies on this
exchange. For more information visit: http://www.aspenpharma.com/

Date: 01/03/2017 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story